Idorsia, Allschwil, Switzerland
http://www.idorsia.com

VXN-319
MULTIVALENT VACCINE TARGETING KLEBSIELLA PNEUMONIAE

Prophylactic semi-synthetic O antigen conjugate vaccine
Klebsiella pneumoniae is a superbug that has spread around the world. Incidence of virtually all strains, including those with multi-resistant profiles, is increasing rapidly. Prevention of infection is a critical component to its abatement. Idorsia is developing a multivalent conjugate vaccine with synthetically produced O-antigens to target more than 80% of carbapenem resistant strains. Efficacy of valencies has already been demonstrated in various mouse and rabbit infection models. The work performed with CARB-X support, initiated with Vaxxilon, includes completion of lead optimization and preclinical development, GMP manufacturing, and a Phase I clinical trial.

Current Development Stage: Hit to Lead

CARB-X Investment: Initial investment of up to $1.4m with potential option payments up to $3.1m

Initial CARB-X Investment Date: April 1, 2019